TrueTicker

NIFTY 500 › Chemicals

Chemicals · NIFTY 500

Anupam Rasayan India Ltd.

ANURAS on NSE · 19 Nov 2026

NIFTY 500

1,327.00 ▲ +0.45 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Filings

50 filings of ANURAS since November 2024; the newest 40 below.

board outcome 17, presentation 11, transcript 10, credit rating 7, dividend 3, results 2

FiledTypeSubject
13 Nov 2026transcript
Acquisition, Guidance, Results
Anupam Rasayan India Limited has informed the Exchange about Transcript of Earnings Call on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026.
AI summary

Anupam Rasayan India Ltd filed the transcript of its Q2 and H1 FY27 earnings call held on November 6, 2026, for the quarter and half year ended September 30, 2026.

Management said the Bliss GVS Pharma acquisition was completed on September 28, 2026, giving the company about 50.07% of Bliss GVS equity; consolidated total income for Q2 FY27 was INR821 crores (up 11% YoY) and EBITDA was INR202 crores (EBITDA margin close to 25%).

Management said H1 FY27 consolidated total income was INR1,489 crores (up 21% YoY), EBITDA was INR377 crores (margin 25.5%) and PAT was INR116 crores (up 10% YoY).

Management said the acquisition was funded by a INR300 crore term loan and a INR1,450 crore non-controlling, non-voting instrument raised from investors led by Bain Capital.

Management guided a consolidated EBITDA margin of 22%-24% for Bliss GVS on a steady-state basis and said it would not revise the existing guidance for Anupam despite higher recent margins.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2026presentation
Acquisition, Legal, Results
Anupam Rasayan India Limited has informed the Exchange about Investor Presentation
AI summary

Anupam Rasayan India Ltd filed its Q2 & H1 FY27 investor presentation (unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026).

Consolidated total revenue for Q2 FY27 was ₹821 Cr (up 23% Q-o-Q); consolidated EBITDA ₹202 Cr; consolidated profit after tax ₹65 Cr.

Standalone total revenue for Q2 FY27 was ₹413 Cr; standalone EBITDA ₹141 Cr; standalone profit after tax ₹46 Cr.

H1 FY27 consolidated total revenue was ₹1,489 Cr (up 21% Y-o-Y) and consolidated PAT ₹116 Cr (up 10% Y-o-Y).

Management said it acquired a 50.07% controlling stake in Bliss GVS Pharma Limited, completed on September 28, 2026, and signed a six-year supply contract with a US-based specialty metal manufacturer.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Nov 2026board outcome
Results
Anupam Rasayan India Limited has submitted to the Exchange, the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026.
AI summary

Board outcome filing: the Board of Anupam Rasayan India Ltd approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, on November 06, 2026 (meeting 02:33 p.m. to 03:22 p.m. IST).

Standalone revenue from operations for Q2 FY27 (quarter ended September 30, 2026) was INR 3,971.87 million, against INR 5,879.26 million in the year-ago quarter.

Standalone profit after tax for the quarter was INR 456.50 million, against INR 413.99 million a year earlier; basic EPS was INR 4.01 (not annualised).

Standalone revenue from operations for the half year ended September 30, 2026 was INR 7,259.92 million, against INR 9,036.20 million a year earlier; half-year profit after tax was INR 776.55 million.

The filing includes the statutory auditor's limited review reports from Natvarlal Vepari & Co, which state nothing has come to their attention that causes them to believe the statements contain material misstatement.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Sep 2026board outcome
Capex, Dividend / buy-back, Guidance
Anupam Rasayan India Limited has informed the Exchange regarding Outcome of Board Meeting held on September 19, 2026.
AI summary

Anupam Rasayan India Limited filed the outcome of its board meeting held on September 19, 2026, approving issuance of up to 16,000 secured, rated, unlisted, redeemable non-convertible debentures of INR 1,00,000 each, aggregating up to INR 160,00,00,000 (INR 160 crore), in one tranche on a private placement basis.

The debentures are proposed to be issued to Aditya Birla Capital Limited, with CTL Trusteeship Limited as debenture trustee; deemed date of allotment is September 21, 2026 and final maturity is October 21, 2027.

Coupon is 10.25% p.a.; INR 99,500 per debenture is payable on or before October 21, 2026, and the residual principal of INR 500 per debenture on October 21, 2027.

Security includes a first ranking exclusive pledge over certain shares held by promoters Anand Sureshbhai Desai, Mona Anandbhai Desai, Shraddha Anand Desai and Rehash Industrial and Resins Chemicals Private Limited, plus hypothecation of an Axis Bank escrow account.

Proceeds are proposed for repayment of existing debt, investment in group companies and/or general corporate purposes.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Sep 2026board outcome
Acquisition, Legal
Anupam Rasayan India Limited has informed the Exchange regarding Outcome of Board Meeting held on September 17, 2026.
AI summary

Board of Anupam Rasayan India Ltd approved, at its meeting on September 17, 2026, execution of security documents for financing to wholly-owned subsidiary Mates Visa Consultancy Private Limited.

Mates proposes to issue up to 30,000 senior secured unrated unlisted redeemable NCDs of INR 1,00,000 face value each, aggregating up to INR 300 crore, on a private placement basis.

Approved documents include a pledge over 100% of Mates' equity shares, an unconditional and irrevocable corporate guarantee to the debenture trustee, and a call option agreement with Purebliss Pharma Solutions Private Limited.

Also approved is a pledge over the company's 15% stake in Purebliss Pharma Solutions Private Limited, for financing availed by Purebliss.

Execution of the documents is still pending and will be separately intimated to the exchanges on signing.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Sep 2026board outcome
Acquisition, Dividend / buy-back, Management change
Anupam Rasayan India Limited has informed the Exchange regarding Outcome of Board Meeting held on September 07, 2026.
AI summary

Board of Anupam Rasayan India Ltd approved the notice for its 23rd AGM on September 30, 2026 (video conference), with record date September 18, 2026 for final dividend for FY2025-26 if declared at the AGM.

Board fixed September 23, 2026 as the voting eligibility cut-off date, speaker registration from September 24 to 26, 2026, and remote e-voting from September 27 to 29, 2026 (ends 5:00 PM IST).

Board appointed M D Baid & Associates, Practicing Company Secretaries, as scrutinizer for the e-voting process.

Board appointed Ms. Hetvi Vyas as Deputy Chief Financial Officer and Key Managerial Personnel.

Board approved acquisition of 2,60,065 equity shares of Tanfac Industries Limited (face value Rs. 5) at Rs. 2,341 each on a preferential issue basis, for aggregate consideration of Rs. 60,88,12,165.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Aug 2026credit rating
Acquisition, Rating
Anupam Rasayan India Limited has informed the Exchange about Credit Rating
AI summary

Anupam Rasayan India Ltd filed an intimation under Regulation 30 that Crisil Ratings has continued its ratings on the company's bank facilities and non-convertible debentures on 'Rating Watch with Developing Implications'.

Rated bank loan facilities of Rs 1,620 crore: long term Crisil A+/Watch Developing and short term Crisil A1/Watch Developing.

Rs 160 crore non-convertible debentures: Crisil A+/Watch Developing.

Crisil says the watch follows the announced acquisition of a 43.3–48.2% equity stake in Bliss GVS Pharma Ltd, expected to complete in September 2026, and it expects the rating to move by no more than one notch.

Crisil's rationale reports fiscal 2026 operating income of Rs 2,365.46 crore (fiscal 2025: Rs 1,438.72 crore) and PAT of Rs 222.20 crore (fiscal 2025: Rs 159.85 crore).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 Aug 2026transcript
Acquisition, Capex, Guidance, Results
Anupam Rasayan India Limited has informed the Exchange about Transcript of Earnings Call on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.
AI summary

Anupam Rasayan India Ltd filed the transcript of its Q1 FY27 earnings call, held on August 14, 2026, for the quarter ended June 30, 2026.

Management said consolidated total income rose 36% year-on-year to INR668 crores, with EBITDA of INR175 crores (26% margin) and PAT of INR51 crores, up 6% year-on-year.

Management said the major capex cycle is complete and it does not foresee significant capex needed for the existing Anupam platform in the near term.

Management said the Bliss GVS Pharma acquisition is expected to conclude by the first half of September 2026, after the SEBI approval and open offer closed on August 10.

Management guided consolidated EBITDA margins of 22% to 24% and standalone margins of 24% to 26%, and expects the BASQUEVOLT LOI opportunity (about USD300 million over 10 years) to begin commercialization in FY27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Aug 2026presentation
Acquisition, Guidance, Results
Anupam Rasayan India Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation for Q1 FY27 (quarter ended June 30, 2026) on the unaudited standalone and consolidated financial results, filed under Regulation 30 of the SEBI LODR Regulations.

Consolidated total income for Q1 FY27 was Rs 6,675 Mn, up 36% year-on-year; consolidated EBITDA was Rs 1,749 Mn, up 35%; consolidated profit after tax was Rs 512 Mn, up 6%.

Standalone total income for Q1 FY27 was Rs 3,349 Mn, up 4% year-on-year; standalone EBITDA was Rs 1,155 Mn, up 17%; standalone profit after tax was Rs 320 Mn, up 8%.

Management said the company signed a Letter of Intent with BASQUEVOLT, S.A. with a potential revenue opportunity of about US$300 million over ten years, with commercialization expected in FY27.

Management said the proposed acquisition of Bliss GVS Pharma is progressing as planned and the Jayhawk Fine Chemicals acquisition has been completed.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Aug 2026board outcome
Management change, Results
Anupam Rasayan India Limited has submitted to the Exchange, the Standalone and Consolidated Financial Results for the quarter ended Jun 30, 2026.
AI summary

Board outcome filed on August 14, 2026 (meeting held 08:48 to 09:36 IST) approving unaudited standalone and consolidated results for the quarter ended June 30, 2026, with limited review reports from the statutory auditor.

Standalone revenue from operations for Q1 FY27 (quarter ended Jun-26) was INR 3,288.05 million, against INR 3,705.79 million in Mar-26 and INR 3,156.94 million in Jun-25.

Standalone profit after tax was INR 320.06 million for Jun-26, against INR 423.84 million in Mar-26 and INR 296.94 million in Jun-25; basic EPS was INR 2.81 (not annualised).

The Board approved the appointment of Mr. Ravi Desai as Chief Operating Officer with effect from August 14, 2026, while he continues as a Key Managerial Personnel.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Jun 2026credit rating
Rating
Anupam Rasayan India Limited has informed the Exchange about Credit Rating- Update by the credit rating agency India Ratings and Research (Ind-Ra)
AI summary

Anupam Rasayan India Ltd filed an intimation under Regulation 30 of the SEBI Listing Regulations about a credit rating update by India Ratings and Research (Ind-Ra).

Issuer rating is IND AA-/Rating Watch with Negative Implications, with the rating watch maintained.

Bank loan facilities of INR 7,275 million (reduced from INR 11,961 million) carry IND AA-/Rating Watch with Negative Implications, with the watch maintained.

Bank loan facilities of INR 8,880 million carry IND AA-/IND A1+ ratings, both on Rating Watch with Negative Implications, with the watch maintained; non-convertible debentures of INR 1,600 million were newly assigned IND AA-/Rating Watch with Negative Implications.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Jun 2026credit rating
Acquisition, Legal, Rating
Anupam Rasayan India Limited has informed the Exchange about Credit Rating- Update by the credit rating agency Crisil Ratings Limited
AI summary

Anupam Rasayan India Ltd filed an intimation of credit rating action by Crisil Ratings Limited, dated June 2, 2026.

Total bank loan facilities rated enhanced to Rs 1,620 crore from Rs 1,369.82 crore; long-term rating Crisil A+/Watch Developing and short-term rating Crisil A1/Watch Developing, both placed on Rating Watch with Developing Implications.

Rs 160 crore non-convertible debentures assigned Crisil A+/Watch Developing, also placed on Rating Watch with Developing Implications.

Crisil placed the ratings on watch following the company's announced acquisition of a 43.3-48.2% equity stake in Bliss GVS Pharma Ltd; the rating agency expects the rating to not move more than a notch.

Crisil noted the acquisition may be funded through debt of Rs 300 crore, with the balance from a global investment management fund via non-controlling, non-voting equity.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 May 2026transcript
Acquisition, Capex, Dividend / buy-back, Guidance, Results
Anupam Rasayan India Limited has informed the Exchange about Transcript
AI summary

Anupam Rasayan filed the transcript of its Q4 and FY26 earnings call held on May 25, 2026.

Management said FY26 operating cash flow was INR334 crores and FY26 capex was INR315 crores, with all plants now commercialized and no major capex envisaged near term.

Consolidated FY26 revenue from operations was INR2,384 crores (up 65% Y-o-Y) and PAT was INR222 crores; Q4 FY26 total income was INR639 crores (up 26% Y-o-Y) and PAT was INR56 crores.

Management said it has entered a definitive agreement to acquire a 43.3% to 48.2% stake in Bliss GVS Pharma with an open offer, funded partly by about INR300 crores of NCDs, and that the acquisition is EPS accretive from day 1.

Management expects 20% to 30% CAGR in standalone revenue over the next 3 to 5 years and estimated maintenance capex of INR50 crores to INR75 crores.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 May 2026presentation
Acquisition, Capex, Legal
Anupam Rasayan India Limited has informed the Exchange about Investor Presentation
AI summary

Anupam Rasayan India Ltd filed an investor presentation dated May 2026 on its acquisition of Bliss GVS Pharma Limited, also to be hosted on the company website.

The presentation describes Bliss GVS Pharma as an Indian pharmaceutical formulations company with 6 manufacturing facilities in Maharashtra, 150+ brands and a first EU-GMP certified suppositories manufacturer in India.

Bliss GVS Pharma performance trend shown: revenue Rs 752 crore, EBITDA Rs 117 crore and PAT Rs 77 crore for FY23, rising to revenue Rs 810 crore, EBITDA Rs 164 crore and PAT Rs 135 crore for FY26 (chart figures as read from the slide).

Transaction structure: Anupam, through a wholly owned subsidiary, to make an open offer to public shareholders for 43.3% to 48.2% stake, with the balance via non-controlling, non-voting equity instrument, enabling consolidation of Bliss GVS Pharma.

Source of funds includes a term loan of about Rs 300 crore from a lender.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 May 2026presentation
Acquisition, Results
Anupam Rasayan India Limited has informed the Exchange about Investor Presentation
AI summary

Anupam Rasayan India Ltd filed its Q4 & FY26 investor presentation, based on audited standalone and consolidated results for the quarter and year ended March 31, 2026.

FY26 consolidated total income was ₹23,836 Mn (up 65% YoY), consolidated EBITDA ₹5,430 Mn (up 32%) and profit after tax ₹2,222 Mn (up 39%).

Q4FY26 consolidated total income was ₹6,392 Mn (up 26% YoY), EBITDA ₹1,407 Mn (down 6%) and PAT ₹560 Mn (down 11%).

The company completed the acquisition of Jayhawk Fine Chemicals during the year and signed a definitive agreement to acquire a controlling stake in Bliss GVS Pharma.

Management said FY26 was a landmark year, with the highest-ever annual sales and operating cash flow of ₹3,343 Mn, and said it is well-positioned for the next phase of growth.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 May 2026dividend
Acquisition, Dividend / buy-back, Management change, Results
Anupam Rasayan India Limited has informed the Exchange that Board of Directors at its meeting held on May 23, 2026, recommended the payment of Final Dividend of Rs. 1.5/- per equity share @ 15% of face value of INR 10/- each of the Company,
AI summary

Outcome of board meeting held on May 23, 2026: audited standalone and consolidated financial results for quarter and year ended March 31, 2026 approved, with unmodified audit opinion from Natvarlal Vepari & Co.

Board recommended final dividend of INR 1.5 per equity share (15% of face value of INR 10), subject to approval at the 23rd AGM.

Board approved acquisition of up to 74.20% of equity shares and control of Bliss GVS Pharma Limited.

Board approved raising INR 160,00,00,000 via 16,000 secured, rated, unlisted, redeemable NCDs of INR 1,00,000 face value each on private placement.

Board approved re-appointment of KB Daliya & Associates as internal auditor and Bhanwarlal Gurjar & Co. as cost auditor for FY 2026-27; accepted resignation of Mr. Vishal Thakkar as Deputy CFO and KMP.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 May 2026board outcome
Acquisition, Dividend / buy-back, Management change, Results
Anupam Rasayan India Limited has submitted to the Exchange, the financial results for the quarter and financial year ended March 31, 2026.
AI summary

Board of Anupam Rasayan India Ltd approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026; statutory auditor Natvarlal Vepari & Co issued unmodified audit reports.

Board recommended a final dividend of INR 1.5 per equity share (15% of face value of INR 10), subject to shareholder approval at the 23rd AGM.

Board approved acquisition of up to 74.20% of the paid-up equity share capital and control of Bliss GVS Pharma Limited.

Board approved raising INR 160,00,00,000 via 16,000 secured, rated, unlisted, redeemable NCDs of INR 1,00,000 face value each on a private placement basis.

Board re-appointed KB Daliya & Associates as internal auditor and Bhanwarlal Gurjar & Co as cost auditor for FY 2026-27; accepted resignation of Mr. Vishal Thakkar as Deputy CFO and KMP with immediate effect.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Apr 2026board outcome
Legal
Anupam Rasayan India Limited has informed the Exchange regarding Outcome of Board Meeting held on April 06, 2026.
AI summary

Anupam Rasayan India Ltd filed the outcome of its board meeting held on April 06, 2026.

The board approved a postal ballot notice seeking shareholder consent, by remote e-voting only, for guarantees and security interests tied to a credit facility availed by Doriath S.à.r.l., effective if Doriath ceases to be a wholly owned subsidiary.

The board also approved a special resolution on creating security interests over shares and assets of Doriath S.à.r.l. and Jayhawk Fine Chemicals Corporation to secure that facility.

Cut-off date is April 03, 2026; remote e-voting runs from April 08, 2026 to May 07, 2026 (till 5:00 p.m. IST).

M/s. M. D. Baid & Associates, Practicing Company Secretaries, was appointed as scrutinizer.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Mar 2026credit rating
Rating
Anupam Rasayan India Limited has informed the Exchange about Credit Rating
AI summary

Anupam Rasayan India Ltd filed an intimation under Regulation 30 of the SEBI Listing Regulations dated March 18, 2026.

Crisil Ratings Limited updated the credit rating on total bank loan facilities of Rs. 1369.82 crore.

Long-term rating: Crisil A+/Stable, removed from 'Rating Watch with Negative Implications' and reaffirmed.

Short-term rating: Crisil A1, removed from 'Rating Watch with Negative Implications' and reaffirmed.

The Rating Rationale dated March 18, 2026 is enclosed with the filing.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Feb 2026transcript
Acquisition, Guidance, Results
Anupam Rasayan India Limited has informed the Exchange about Transcript
AI summary

Anupam Rasayan India filed the transcript of its Q3 FY26 / 9MFY26 earnings call held on February 14, 2026, on the unaudited results for the quarter and nine months ended December 31, 2025.

Managing Director Anand Desai said consolidated 9MFY26 revenue was INR1,730 crores (up 84% Y-o-Y), EBITDA INR402 crores (up 53%) and PAT INR166 crores (up 71%); Q3 FY26 revenue was INR512 crores (up 31%), EBITDA INR130 crores and PAT INR61 crores.

Management said it signed a definitive agreement to acquire 100% equity in US-based Jayhawk Fine Chemicals from the CABB Group, expected to close in the coming weeks, and expects it to be EPS accretive from day one.

CFO-side commentary from Vishal Thakkar: consolidated working capital intensity is around 250 days, with a target of 220-200 days in the near term and below 200 (about 180) days in FY27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Feb 2026presentation
Acquisition, Results
Anupam Rasayan India Limited has informed the Exchange about Investor Presentation
AI summary

Anupam Rasayan India Ltd filed the investor presentation on its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.

Consolidated nine-month total revenue was ₹17,297 Mn (up 84% Y-o-Y), EBITDA ₹4,024 Mn (up 53%) and PAT ₹1,662 Mn (up 71%).

Consolidated Q3 FY26 total revenue was ₹5,124 Mn (up 31% Y-o-Y), EBITDA ₹1,296 Mn (up 7%) and PAT ₹606 Mn (up 12%).

Standalone nine-month total revenue was ₹13,050 Mn (up 130%), with EBITDA of ₹3,217 Mn and PAT of ₹1,190 Mn.

Management (MD Anand S Desai) said the company signed a definitive agreement to acquire Jayhawk Fine Chemicals Corporation in the United States and remains confident in sustaining its growth trajectory.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Feb 2026board outcome
Results
Anupam Rasayan India Limited has submitted to the Exchange, the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025.
AI summary

Anupam Rasayan India Ltd's board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, on February 14, 2026.

Standalone revenue from operations for the quarter ended December 31, 2025 was INR 4,013.67 million, against INR 5,879.26 million in the September 2025 quarter and INR 2,120.87 million in the December 2024 quarter.

Standalone profit after tax for the quarter ended December 31, 2025 was INR 479.19 million, against INR 413.99 million in the September 2025 quarter and INR 191.36 million in the December 2024 quarter.

Standalone revenue from operations for the nine months ended December 31, 2025 was INR 13,049.87 million, against INR 5,667.10 million in the corresponding period of 2024.

The Auditor's limited review report on the results was issued by Natvarlal Vepari & Co.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Feb 2026board outcome
Acquisition, Capex, Legal
Anupam Rasayan India Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2026.
AI summary

Anupam Rasayan India Limited filed the outcome of its board meeting held on 12 February 2026, ratifying the acquisition of 100% equity in Doriath S.à r.l. (completed 10 February 2026) and 15% equity in Batam S.à r.l. (consideration paid, completion in process), both via Palaos S.à r.l.

The board approved assigning the Company's rights under the SPA for acquiring Monitchem Kansas S.à r.l. and its subsidiaries to Doriath, a wholly owned subsidiary.

The board approved credit facilities of USD 20,000,000 for Doriath from Altis XII Pte. Ltd. and an ECB facility of USD 30,000,000 for the Company from Axis Bank Limited, IBU GIFT City and other syndicated lenders.

The board approved corporate guarantees, security creation (hypothecation, mortgage, pledge) and a loan of up to USD 20,000,000 from the Company to Doriath in connection with these facilities.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Dec 2025transcript
Acquisition, Guidance
Anupam Rasayan India Limited has informed the Exchange about Transcript
AI summary

Anupam Rasayan filed the transcript of its Investor Call on US Acquisition Update, held December 15, 2025.

On December 9, 2025, the company signed a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals, a US-based specialty chemicals company from the CABB Group, headquartered in Kansas.

Management said Jayhawk reported about USD78 million revenue in CY24 with EBITDA margins of around 19%, and the enterprise value is about 134 million, around 9x CY24 EBITDA.

Total purchase consideration is about 150 million, with about 110 million to be invested by a global investment management firm via Class B non-voting shares; management expects the deal to be EPS-accretive from day one.

Management said the combined entity would have pro-forma revenue of about USD243 million and EBITDA of about USD61 million.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Dec 2025credit rating
Rating
Anupam Rasayan India Limited has informed the Exchange about Credit Rating
AI summary

Anupam Rasayan India Ltd filed an intimation under Regulation 30 of the SEBI Listing Regulations dated December 18, 2025.

Crisil Ratings Limited updated the credit rating of the company, with total bank loan facilities rated at Rs. 1369.82 crore.

Long-term rating: Crisil A+/Watch Negative (placed on 'Rating Watch with Negative Implications').

Short-term rating: Crisil A1/Watch Negative (placed on 'Rating Watch with Negative Implications').

The Rating Rationale dated December 18, 2025 is enclosed with the filing.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Dec 2025credit rating
Rating
Anupam Rasayan India Limited has informed the Exchange about Credit Rating
AI summary

Anupam Rasayan India Ltd filed an intimation under Regulation 30 of the SEBI Listing Regulations on credit rating action by India Ratings and Research (Ind-Ra).

Ind-Ra placed the Long Term Issuer Rating of IND AA- on Rating Watch with Negative Implications.

Ind-Ra placed the bank loan facilities (long term/short term) of INR 11,961 million on Rating Watch with Negative Implications, at IND AA-/IND A1+ ratings.

The Rating Rationale is dated December 18, 2025, and was enclosed with the filing.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
09 Dec 2025presentation
Acquisition
Anupam Rasayan India Limited has informed the Exchange about Investor Presentation
AI summary

Anupam Rasayan India Ltd filed an investor presentation on its Jayhawk acquisition announcement, dated December 9, 2025.

The company has signed a definitive agreement to acquire 100% equity in Jayhawk Fine Chemicals LLC, a U.S.-based specialty chemicals company, at an enterprise value of ~$134M (total purchase consideration ~$150M including ~$16M of cash and cash equivalents).

The acquisition will be funded through internal accruals, debt and quasi equity.

Jayhawk had ~$78M revenue and ~$15M EBITDA (~19% margin) in 2024, with ~140 FTEs and a multi-purpose site of ~3M sq. m in Kansas, U.S.; it was founded in 1941 and is part of the CABB Group.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
09 Dec 2025board outcome
Acquisition, Dividend / buy-back, Legal
Anupam Rasayan India Limited has informed the Exchange regarding Outcome of Board Meeting held on December 09, 2025.
AI summary

Anupam Rasayan India Limited filed the outcome of its board meeting held on December 9, 2025.

The board approved acquisition of 100% of Monitchem Kansas S.à r.l and its subsidiaries (Kansas HoldCo Inc., Kansas HoldCo 1, Inc., Jayhawk Fine Chemicals Corporation) from CABB Europe GmbH, and the SPA was executed the same day; the target's FY24-25 turnover is stated as US$78,306,786.

The board also approved purchase of a loan receivable from CABB GmbH, with total cost up to USD 155 million; cash consideration; completion indicated for January–February 2026.

The board approved a postal ballot (e-voting from December 11, 2025 to January 9, 2026) seeking special resolutions on increasing borrowing limits, selling or disposing of the whole or substantially the whole undertaking, and investments, loans and guarantees above Section 186 limits.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 Nov 2025board outcome
Management change
Anupam Rasayan India Limited has informed the Exchange regarding Outcome of Board Meeting held on November 21, 2025.
AI summary

Board of Anupam Rasayan India Ltd approved a Postal Ballot Notice seeking shareholder approval, by special resolution, for appointment of Mr. Milind Madan Talathi (DIN: 07321958) as Non-Executive Independent Director for 3 consecutive years from September 25, 2025 to September 24, 2028.

Postal Ballot notice to be sent to members on November 22, 2025; cut-off date for eligibility is November 20, 2025.

Remote e-voting runs from November 23, 2025 (9:00 a.m. IST) to December 22, 2025 (5:00 p.m. IST).

M/s. M.D. Baid & Associates, Practicing Company Secretaries, Surat, appointed as Scrutinizer for the postal ballot.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Oct 2025transcript
Acquisition, Guidance, Results
Anupam Rasayan India Limited has informed the Exchange about Transcript of earnings call
AI summary

Anupam Rasayan India Ltd filed the transcript of its Q2 and H1 FY26 earnings call held on October 17, 2025, on the unaudited results for the quarter and half year ended September 30, 2025.

Management reported consolidated revenue from operations of INR 731.4 crore in Q2 FY26 (up 148.8% YoY) and INR 1,217.2 crore in H1 FY26 (up 122.1% YoY), with consolidated EBITDA margin of about 19.5% in Q2 and 22.2% in H1, and PAT of INR 57.15 crore in Q2 and INR 105.61 crore in H1.

Management expects total revenue growth of over 50% in FY26 and EBITDA margins to stabilise around 25% (plus or minus 1 percentage point), and expects working capital days to fall to about 200 days in the near term.

Management said about 25-30% of Q2 revenue came from liquidation of older inventory, and that the company is actively looking for inorganic/M&A assets in the polymer space.

On standalone receivables, management attributed a roughly INR 300-350 crore difference to a timing gap in remittances from US and Europe subsidiaries.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Oct 2025presentation
Results
Anupam Rasayan India Limited has informed the Exchange about Investor Presentation
AI summary

Anupam Rasayan India Ltd filed an investor presentation on its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025.

Consolidated H1 FY26: total revenue ₹12,299 Mn (up 121% YoY), EBITDA ₹2,728 Mn (up 93% YoY), PAT ₹1,056 Mn (up 147% YoY).

Consolidated Q2 FY26: total revenue ₹7,392 Mn (up 149% YoY), EBITDA ₹1,436 Mn (up 74% YoY), PAT ₹572 Mn (up 87% YoY).

Standalone H1 FY26: total revenue ₹9,161 Mn (up 152% YoY), PAT ₹711 Mn (up 360% YoY); Standalone Q2 FY26 total revenue ₹5,956 Mn (up 206% YoY), PAT ₹414 Mn (up 195% YoY).

Managing Director Anand S Desai said Q2 FY26 was one of the best quarters for the company, with consolidated revenue from operations of INR 739 crore, and that H1 FY26 revenue has already surpassed total FY25 revenue; subsidiary Tanfac Industries reported H1 FY26 revenue of INR 345 crore (up 67% YoY).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Oct 2025board outcome
Results
Anupam Rasayan India Limited has submitted to the Exchange, the financial results for the quarter and half year ended September 30, 2025.
AI summary

Board of Anupam Rasayan India Ltd approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, at a meeting held October 17, 2025 (9:02 a.m. to 9:38 a.m. IST).

Standalone revenue from operations for Q2 FY26 was INR 5,879.26 million, against INR 3,156.94 million in Q1 FY26 and INR 1,906.71 million in Q2 FY25.

Standalone profit after tax for Q2 FY26 was INR 413.99 million, against INR 296.94 million in Q1 FY26 and INR 140.33 million in Q2 FY25.

Standalone revenue from operations for the half year ended September 30, 2025 was INR 9,036.20 million, against INR 3,546.23 million in the half year ended September 30, 2024.

Standalone basic earnings per share for Q2 FY26 was INR 3.67 (not annualised).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Sep 2025board outcome
Legal, Management change
Anupam Rasayan India Limited has informed the exchange regarding Outcome of Board meeting held on September 01, 2025.
AI summary

Board of Anupam Rasayan India Ltd approved appointment of Natvarlal Vepari & Co., Chartered Accountants, as Statutory Auditor, and M.D. Baid & Associates as Secretarial Auditor, subject to member approval at the 22nd AGM.

Board approved re-appointment of Mr. Anand Sureshbhai Desai as Managing Director and Mrs. Mona Anandbhai Desai as Whole-time Director, each for 5 years effective April 01, 2026, subject to member approval.

Board approved the notice for the 22nd AGM on Friday, September 26, 2025 at 05:00 P.M. IST via video conference/other audio-visual means.

Record/cut-off date for member voting eligibility is Friday, September 19, 2025; speaker registration runs September 20-22, 2025; remote e-voting runs September 23-25, 2025 (ending 05:00 P.M. IST).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Aug 2025transcript
Capex, Dividend / buy-back, Guidance, Results
ANURAS Anupam Rasayan India Limited has informed the Exchange about Transcript of the Earnings Call on the Unaudited Financial Results Standalone and Consolidated for the quarter ended June 30, 2025.
AI summary

Anupam Rasayan India Ltd filed the transcript of its Q1 FY26 earnings call held on August 14, 2025, on the unaudited results for the quarter ended June 30, 2025.

Management said consolidated revenue from operations was INR486 crores, up 91% year-on-year, with consolidated EBITDA of INR129 crores (26.3% margin) and profit after tax of INR49 crores; standalone revenue was INR316 crores, up 93%.

Management said it signed a long-term master purchase agreement with a Japan-based fluorochemicals conglomerate and a letter of intent with E-Lyte Innovations, taking the order book to INR14,646 crores.

Management said all planned capex projects are complete, a preferential issue receipt of INR277.5 crores in July 2025 was used in part to repay INR175 crores of term debt, and the company is long-term net debt free.

Management expects a considerable reduction in working capital in coming quarters as existing inventory is used to fulfil orders.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Aug 2025presentation
Results
Anupam Rasayan India Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation on the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1FY26).

Consolidated total revenue was ₹4,907 Mn, up 89% year-on-year; consolidated EBITDA (incl. other revenue) was ₹1,292 Mn, up 118%; consolidated PAT was ₹485 Mn, up 297%.

Standalone total revenue was ₹3,205 Mn, up 89%; standalone EBITDA (incl. other revenue) was ₹991 Mn, up 133%; standalone PAT was ₹297 Mn.

Management (Managing Director Anand S Desai) said sectoral trends are in the company's favor, pharma and polymer businesses are performing well, and agrochemical recovery is under way.

Management said the order book now stands at ₹14,646 crore following two new agreements with Japanese and US-based multinational companies, and that exports were 58% of revenue from operations in Q1FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Aug 2025presentation
Results
Anupam Rasayan India Limited has informed the Exchange about Investor Presentation in respect of the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2025
AI summary

Investor presentation on unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1FY26), filed under Regulation 30 of SEBI LODR.

Consolidated total revenue was ₹4,907 Mn, up 89% year-on-year; consolidated EBITDA (incl. other revenue) was ₹1,292 Mn, up 118%; consolidated PAT was ₹485 Mn, up 297%.

Standalone total revenue was ₹3,205 Mn, up 89% year-on-year; standalone EBITDA was ₹991 Mn, up 133%; standalone PAT was ₹297 Mn.

Company added 1 new product in Q1FY26, taking the total to 80 products.

Managing Director Anand S Desai said sectoral trends are in the company's favour, pharma and polymer businesses are performing well, and agrochemical segment is recovering.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Aug 2025board outcome
Dividend / buy-back, Results
Anupam Rasayan India Limited has submitted to the Exchange, the unaudited standalone and consolidated financial results for the period ended June 30, 2025.
AI summary

Board of Anupam Rasayan India Limited approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 at a meeting held August 13, 2025.

Standalone revenue from operations for Q1 FY26 was INR 3,156.94 million, versus INR 3,306.73 million in the quarter ended March 31, 2025 and INR 1,639.52 million in the quarter ended June 30, 2024.

Standalone profit after tax for the quarter ended June 30, 2025 was INR 296.94 million, versus INR 380.91 million in the preceding quarter and INR 14.15 million in the year-ago quarter.

An interim dividend for FY 2024-25 of INR 0.75 per equity share (face value INR 10) was declared and paid after the quarter end, as stated in the notes.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 Jul 2025dividend
Acquisition, Dividend / buy-back
Anupam Rasayan India Limited has informed the Exchange that Board of Directors at its meeting held on July 15, 2025, declared Interim Dividend of Rs. 0.75 per equity share and fixed record date for this purpose.
AI summary

Anupam Rasayan India Ltd filed the outcome of its board meeting held on July 15, 2025.

The board declared an interim dividend for FY 2024-25 of INR 0.75 per equity share (7.5% of face value of INR 10), with record date July 21, 2025, payable on or before August 13, 2025.

The board approved allotment of 39,14,886 equity shares on preferential basis at INR 945.11 per share on conversion of warrants, receiving INR 2775.00 million (remaining 75% of issue price).

Allottees include Lata Manek Bhanshali (5,29,038 shares), Zeal Global Opportunities Fund (16,92,924 shares) and Zinnia Global Fund PCC - Cell Dewcap (16,92,924 shares).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
15 Jul 2025dividend
Capex, Dividend / buy-back
Anupam Rasayan India Limited has informed the Exchange that Board of Directors at its meeting held on July 15, 2025, declared Interim Dividend of 0.75 per equity share and fixed the record date for this purpose.
AI summary

Anupam Rasayan India Ltd filed the outcome of its board meeting held on July 15, 2025.

The board declared an interim dividend for FY 2024-25 of INR 0.75 per equity share (7.5% of face value of INR 10).

The record date for the interim dividend is July 21, 2025, and payment is to be made on or before August 13, 2025.

The board also approved allotment of 39,14,886 equity shares on preferential basis at INR 945.11 per share, on conversion of warrants, for INR 2775.00 million (remaining 75% of issue price).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 May 2025transcript
Capex, Guidance, Results
Anupam Rasayan India Limited has informed the Exchange about Transcript
AI summary

Anupam Rasayan India Limited filed the transcript of its Q4 and FY25 earnings conference call, held on May 24, 2025, on the audited standalone and consolidated results.

Management said consolidated revenue for Q4 FY25 was INR506 crores, up 22% Y-o-Y and 31% Q-o-Q, and FY25 consolidated revenue was INR1,448 crores, down 4% Y-o-Y; Q4 FY25 EBITDA margin was about 30% and FY25 EBITDA margin about 29%.

Management said nearly INR670 crores of the planned capex was completed as of March 31, 2025, and approximately INR185 crores of long-term debt is expected to be repaid from warrant conversion proceeds in FY26.

Management said the order book stands at around INR14,646 crores over 4 to 10 years, with INR3,100 crores of LOIs and contracts already commercialized and contributing over 20% of FY25 revenue.

Management expects a return to historical growth rates of 25% to 30% from FY26 onward and said US and Japan contributions are expected to grow in FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in